- Home
- NCV vs MNPR Comparison
NCV vs MNPR Comparison
Compare NCV & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCV | MNPR |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.7M | 368.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NCV | MNPR |
|---|---|---|
| Price | $17.08 | $62.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $107.00 |
| AVG Volume (30 Days) | 80.0K | ★ 164.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.31 | $28.40 |
| 52 Week High | $17.53 | $105.00 |
Technical Indicators
Market Signals| Indicator | NCV | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 57.35 |
| Support Level | $14.67 | $51.71 |
| Resistance Level | $17.53 | $67.90 |
| Average True Range (ATR) | 0.34 | 5.62 |
| MACD | -0.08 | 0.25 |
| Stochastic Oscillator | 49.53 | 69.41 |
Price Performance
Historical ComparisonAbout NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.